<DOC>
	<DOCNO>NCT01232283</DOCNO>
	<brief_summary>This study evaluate effect experimental ( test ) study drug call apremilast . Apremilast work lowering chemical affect psoriasis therefore improve symptoms psoriasis . The purpose study test apremilast compare effect placebo ( inactive substance contains medicine form drug ) . This study test efficacy ( improvement sign symptom ) safety apremilast patient moderate severe psoriasis .</brief_summary>
	<brief_title>Study Evaluate Safety Effectiveness Oral Apremilast ( CC-10004 ) Patients With Moderate Severe Plaque Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Males female , â‰¥ 18 year age time sign informed consent document 2 . Diagnosis chronic plaque psoriasis least 12 month prior Screening . Have moderate severe plaque psoriasis Screening Baseline 3 . Must meet laboratory criterion 4 . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . FCBP engage activity conception possible must use 2 form contraception describe Study Doctor study medication least 28 day take last dose study medication 5 . Male subject ( include vasectomy ) engage activity conception possible must use barrier contraception ( latex condom nonlatex condom NOT make natural [ animal ] membrane [ eg , polyurethane ] ) study medication least 28 day last dose study medication . 1 . Other psoriasis , history clinically significant ( determined Investigator ) major uncontrolled disease . 2 . Pregnant breast feed 3 . History allergy component study drug 4 . Hepatitis B surface antigen positive Screening 5 . Antihepatitis C antibody positive Screening 6 . Active tuberculosis ( TB ) history incompletely treat TB 7 . Clinically significant abnormality 12Lead ECG Screening 8 . Clinically significant abnormal chest xray 9 . History positive human immunodeficiency virus ( HIV ) , congenital acquire immunodeficiency 10 . Active substance abuse history substance abuse within 6 month prior Screening 11 . Bacterial infection require treatment oral injectable antibiotic , significant viral fungal infection , within 4 week Screening 12 . Malignancy history malignancy ( except treat [ ie , cure ] basal cell squamous cell situ skin carcinoma treat [ ie , cure ] cervical intraepithelial neoplasia [ CIN ] carcinoma situ cervix evidence recurrence within previous 5 year ) 13 . Psoriasis flare rebound within 4 week prior Screening 14 . Evidence skin condition would interfere clinical assessment 15 . Topical therapy within 2 week randomization 16 . Systemic therapy psoriasis within 4 week prior randomization 17 . Use phototherapy within 4 week prior randomization ( ie , UVB , PUVA ) 18 . Adalimumab , etanercept , infliximab , certolizumab pegol within 12 week prior randomization 19 . Alefacept , briakinumab , ustekinumab within 24 week prior randomization 20 . Use investigational drug within 4 week prior randomization 21 . Prolonged sun exposure use tan booth ultraviolet ( UV ) light source 22 . Prior treatment apremilast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>